In the recent X-ACT (Xeloda in Adjuvant Colon cancer Therapy) trial, oral capecitabine (Xeloda) demonstrated superior efficacy and an improved safety profile compared with infused fluorouracil + leucovorin (folinic acid) [FU+LV] in patients with Dukes' C colorectal cancer. We used the X-ACT results to determine the cost effectiveness of capecitabine compared with FU+LV from the perspective of the Italian National Health Service (NHS).
Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting / Di Costanzo, F., Ravasio, R., Sobrero, A., Bertetto, O., Vinante, O., Luppi, G., Labianca, R., Amadori, D., Barone, C., Carlo Merlano, M., Longo, F., Mansueto, G., Antonuzzo, L., Gasperoni, S.. - In: CLINICAL DRUG INVESTIGATION. - ISSN 1173-2563. - STAMPA. - 28:(2008), pp. 645-655. [10.2165/00044011-200828100-00005]
Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting
Antonuzzo, Lorenzo;Gasperoni, Silvia
2008
Abstract
In the recent X-ACT (Xeloda in Adjuvant Colon cancer Therapy) trial, oral capecitabine (Xeloda) demonstrated superior efficacy and an improved safety profile compared with infused fluorouracil + leucovorin (folinic acid) [FU+LV] in patients with Dukes' C colorectal cancer. We used the X-ACT results to determine the cost effectiveness of capecitabine compared with FU+LV from the perspective of the Italian National Health Service (NHS).
| File | Dimensione | Formato | |
|---|---|---|---|
|
00044011-200828100-00005.pdf
Accesso chiuso
Dimensione
123.05 kB
Formato
Adobe PDF
|
123.05 kB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
